Future of Anti-NGF Agents May Hinge on ‘Unusual’ Meeting of FDA Advisers: Agency
Sponsors of anti-nerve growth factor (anti-NGF) pain drugs could get some answers on their paused trials Monday as a panel of FDA advisers helps the agency decide whether to lift the clinical hold on developing these treatments.
This article is viewable by subscribers only. To view this article, please select an option below.
 |  |
0 comments:
Post a Comment